Taiko Pharmaceutical Co.,Ltd.

TSE:4574 Stock Report

Market Cap: JP¥14.3b

Taiko PharmaceuticalLtd Future Growth

Future criteria checks 1/6

Taiko PharmaceuticalLtd's earnings are forecast to decline at 3.4% per annum while its annual revenue is expected to grow at 9.9% per year. EPS is expected to decline by 13.7% per annum. Return on equity is forecast to be 8.4% in 3 years.

Key information

-3.4%

Earnings growth rate

-13.7%

EPS growth rate

Medical Equipment earnings growth12.1%
Revenue growth rate9.9%
Future return on equity8.4%
Analyst coverage

Low

Last updated19 Dec 2024

Recent future growth updates

Recent updates

Taiko PharmaceuticalLtd (TSE:4574) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 20
Taiko PharmaceuticalLtd (TSE:4574) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Is Taiko PharmaceuticalLtd (TSE:4574) A Risky Investment?

Mar 08
Is Taiko PharmaceuticalLtd (TSE:4574) A Risky Investment?

Taiko Pharmaceutical Co.,Ltd. (TSE:4574) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 08
Taiko Pharmaceutical Co.,Ltd. (TSE:4574) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Earnings and Revenue Growth Forecasts

TSE:4574 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20267,700700N/A1,2601
12/31/20257,300600N/A1,0001
12/31/20246,292898175362N/A
9/30/20246,282-2,335N/AN/AN/A
6/30/20246,492-2,333-357-177N/A
3/31/20246,330-2,896N/AN/AN/A
12/31/20236,120-3,611-421-307N/A
9/30/20236,068-2,275N/AN/AN/A
6/30/20235,671-2,611-1,279-1,237N/A
3/31/20235,586-3,390N/AN/AN/A
12/31/20225,040-4,895-2,078-1,994N/A
9/30/20226,333-10,829N/AN/AN/A
6/30/20228,050-10,020-1,413-967N/A
3/31/20228,649-11,195N/AN/AN/A
12/31/202111,299-9,594-3,195-1,595N/A
12/31/202022,4564,178-4,988-2,021N/A
9/30/202021,5484,6702,3313,515N/A
6/30/202019,3234,220N/AN/AN/A
3/31/202014,9662,4533,2743,493N/A
12/31/201913,3222,255N/AN/AN/A
9/30/201910,9781,6081,3061,595N/A
6/30/201910,5691,480N/AN/AN/A
3/31/201910,4181,4151,2431,748N/A
12/31/20189,9341,227N/AN/AN/A
9/30/20189,6501,266N/A1,400N/A
6/30/20189,3271,033N/AN/AN/A
3/31/20189,4591,094N/A-59N/A
12/31/20178,949951N/AN/AN/A
9/30/20178,9481,071N/A1,357N/A
6/30/20178,6511,183N/AN/AN/A
3/31/20178,2941,049N/A2,697N/A
12/31/20168,2861,317N/AN/AN/A
9/30/20168,069971N/A1,931N/A
6/30/20167,938755N/AN/AN/A
3/31/20168,327840N/A377N/A
12/31/20157,870740N/AN/AN/A
9/30/20158,5651,191N/A559N/A
6/30/20158,9541,549N/AN/AN/A
3/31/20158,9781,770N/A690N/A
12/31/20149,3091,633N/AN/AN/A
9/30/20149,3551,333N/A1,308N/A
6/30/20149,4481,489N/AN/AN/A
3/31/20149,9471,747N/A3,589N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4574's earnings are forecast to decline over the next 3 years (-3.4% per year).

Earnings vs Market: 4574's earnings are forecast to decline over the next 3 years (-3.4% per year).

High Growth Earnings: 4574's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 4574's revenue (9.9% per year) is forecast to grow faster than the JP market (4.2% per year).

High Growth Revenue: 4574's revenue (9.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4574's Return on Equity is forecast to be low in 3 years time (8.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/21 04:51
End of Day Share Price 2025/02/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Taiko Pharmaceutical Co.,Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Masatoshi NagataIchiyoshi Research Institute Inc.
Kenji SakaiMizuho Securities Co., Ltd.
Yukichi OkabeOkasan Securities Co. Ltd.